How Yaz Affects Mood and Depression
Women with a history of depression should be carefully observed when taking Yaz, and the medication should be discontinued if depression recurs to a serious degree. 1
FDA-Labeled Mood Effects
The FDA label for Yaz explicitly acknowledges mood changes as a recognized adverse reaction, occurring in approximately 2% of users in clinical trials. 1 These mood effects include:
- Mood swings
- Depression
- Depressed mood
- Affect lability 1
The official prescribing information mandates careful monitoring of women with prior depression history and discontinuation if serious depression develops. 1
Evidence on Depression Risk: Mixed Findings
The research evidence presents contradictory findings about Yaz's effects on mood:
Evidence Suggesting Increased Risk
The largest Danish registry study (over 1 million women) found that combined oral contraceptives containing drospirenone and ethinyl estradiol were associated with increased antidepressant use, with a relative risk of 1.23 for first antidepressant prescription. 2 This risk was particularly pronounced in the first 6 months of use (RR 1.4) and among adolescents aged 15-19 years (RR 1.8). 2
A 2023 UK Biobank study of 264,557 women demonstrated that the first 2 years of oral contraceptive use carried the highest depression risk (HR 1.71), with adolescent users showing persistent elevated risk even after discontinuation (HR 1.18). 3 Importantly, sibling analysis in this study supported a causal relationship rather than just correlation. 3
Evidence Suggesting Protective or Neutral Effects
Conversely, a 2025 Finnish registry study of 117,360 women found that combined hormonal contraceptives containing drospirenone and ethinyl estradiol were associated with a lower risk of depression (OR 0.86) compared to non-users. 4 This protective pattern was consistent across all age groups, including adolescents. 4
For specific conditions like premenstrual dysphoric disorder, Yaz demonstrated efficacy in reducing mood symptoms compared to placebo, with 48% of users achieving a 50% reduction in symptoms. 5 A postpartum study also showed DRSP improved mood scores at 12 and 24 weeks postpartum. 6
Clinical Interpretation of Contradictory Evidence
The divergent findings likely reflect:
- Individual hormonal sensitivity: Some women experience mood deterioration while others improve, particularly those with hormone-sensitive mood disorders 7
- Healthy user bias: Women who develop mood symptoms often discontinue quickly, potentially skewing long-term observational data 3
- Age-dependent effects: Adolescents appear more vulnerable to mood effects than adult users 2, 3
Practical Clinical Approach
Screen for depression history before prescribing Yaz. 1 Women with current or recent depression require heightened vigilance.
Monitor mood closely during the first 6 months of use, as this represents the highest-risk period for mood deterioration. 2
Exercise particular caution in adolescents (ages 15-19), who demonstrate the highest relative risk for depression development (RR 1.8-2.2 in some studies). 2
Discontinue Yaz immediately if new or worsening depression develops, as mandated by FDA labeling. 1 Do not attempt to manage through the symptoms.
Consider alternative contraception for women with recurrent major depression, multiple depressive episodes, or strong family history of mood disorders. 3, 7
Common Pitfalls
Do not dismiss patient reports of mood changes as "adjustment period" symptoms—the FDA label explicitly warns about this adverse effect. 1 The temporal relationship between starting Yaz and mood symptoms should be taken seriously. 7
Avoid assuming all patients will respond similarly—individual hormonal sensitivity varies dramatically, with some women experiencing improvement in premenstrual mood symptoms while others develop new depression. 5, 6, 7